Illumina has announced that CEO Francis deSouza has resigned from the biotech company. The decision comes just weeks after activist investor Carl Icahn failed to oust deSouza from his role in a heated proxy fight. The board of directors is now searching for a new CEO and considering both internal and external candidates, with Charles Dadswell taking over as CEO in the meantime. DeSouza will remain an advisor until July 31. In a statement, he said, “It has been the privilege of a lifetime to serve Illumina. We have made great progress together, but I believe we are still at the very beginning of the impact Illumina will have on human health by unlocking the power of the genome.” The proxy fight with Icahn was based on his accusations of poor oversight regarding Illumina’s $7.1 billion acquisition of cancer test maker Grail and deSouza’s handling of quarterly results during a press tour. While shareholders voted off Chairman John Thompson, deSouza held onto his role until his recent resignation.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
